Orchestra BioMed
OBIO
22 hedge funds and large institutions have $193M invested in Orchestra BioMed in 2023 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 15 closing their positions.
241% more capital invested
Capital invested by funds: $56.6M → $193M (+$137M)
8% less funds holding
Funds holding: 24 → 22 (-2)
13% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 15
19.19% less ownership
Funds ownership: 50.43% → 31.24% (-19%)
60% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$47.7M |
| 2 |
PA
Perceptive Advisors
New York
|
+$26.4M |
| 3 |
SFG
SVB Financial Group
Dallas,
Texas
|
+$1.47M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.3M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$6.09M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$3.99M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$3.99M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
-$3.92M |
| 5 |
SCM
Sio Capital Management
New York
|
-$2.5M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TCM
26
Tang Capital Management
San Diego,
California
| – | -$3.92M | -392,500 | Closed |
|
|
SCM
27
Sio Capital Management
New York
| – | -$2.5M | -250,000 | Closed |
|
|
DKCM
28
Davidson Kempner Capital Management
New York
| – | -$2.45M | -245,213 | Closed |
|
|
WP
29
Woodline Partners
San Francisco,
California
| – | -$1.26M | -126,061 | Closed |
|
|
GCWM
30
Graham Capital Wealth Management
Washington D.c.,
District of Columbia
| – | -$649K | -65,005 | Closed |
|
|
PCM
31
PenderFund Capital Management
Vancouver,
British Columbia, Canada
| – | -$748K | -55,300 | Closed |
|
|
RL
32
RPO LLC
Stamford,
Connecticut
| – | -$277K | -27,755 | Closed |
|
|
SFM
33
Spartan Fund Management
Toronto, Ontario,
Canada
| – | -$267K | -26,757 | Closed |
|
|
WRBC
34
W.R. Berkley Corp
Greenwich,
Connecticut
| – | -$199K | -19,902 | Closed |
|
35
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$150K | -15,041 | Closed |
|
|
ACM
36
Altium Capital Management
New York
| – | -$99.8K | -10,000 | Closed |
|
|
EC
37
Elequin Capital
New York
| – | -$15.4K | -1,542 | Closed |
|
OBIO Hedge Fund Activity: Q1 2023 in Review
22 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Orchestra BioMed (OBIO) for Q1 2023, worth a combined $193M — up 241% from $56.6M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of OBIO and 13 opened new positions — a net loss of 2 holders — while 5 trimmed existing stakes and 2 added.
The largest buyer was RTW Investments, adding an estimated $47.7M. The largest seller was RA Capital Management, exiting entirely with an estimated $6.09M sold.
- 22 institutional investors held Orchestra BioMed (OBIO) as of Q1 2023, down from 24 in Q4 2022.
- Funds reported $193M of Orchestra BioMed stock for Q1 2023, up 241% quarter-over-quarter.
- 13 funds opened new Orchestra BioMed positions in Q1 2023 and 15 closed out, a net change of -2 holders.
- The largest Orchestra BioMed buyer in Q1 2023 was RTW Investments, an estimated $47.7M added.
- The largest Orchestra BioMed seller in Q1 2023 was RA Capital Management, an estimated $6.09M sold.
Based on aggregated 13F filings for Q1 2023.